ARMP Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 27.96%, SMA50 51.24%, SMA200 150.42%). The stock’s 14-day RSI is 70.33 (overbought), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.72% below its high and over 1105.88% above its low. Average 10-day trading volume of 67.53 thousand shares is significantly above the 3-month average of 44.58 thousand, indicating heightened recent market interest.

Armata Pharmaceuticals, Inc. generated EPS of -$1.32 over the past year. Five-year average earnings growth is 26.8%. Wall Street analysts project EPS growth of -12.29% annually over the next five years. The latest quarter delivered EPS of -$0.42. The next quarter is forecast at -$0.28. Next year's EPS is expected at $53.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $9.00. The high target offers 16.46% upside. The low target suggests -30.12% downside. The mean target is $13.00. This offers 0.93% upside. Armata Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 0.0%. The prior quarter beat by -17.95%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in August 13, 2024.

Armata Pharmaceuticals, Inc. has 36.41 million shares outstanding. The public float is 11.02 million shares, elevated short interest at 2.88% of float. This equals 310.81 thousand shares. The short ratio is 6.69 days. Institutional investors hold 6.75% of the float. Insiders own 69.14%. BIOGEN IDEC INC holds 11.70 million shares, Innoviva Strategic Opportunities LLC has 2.69 million shares and KIRK RANDAL J has 674.17 thousand shares.

Armata Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$10.94. This means the shares are trading below this model’s fair value.

Armata Pharmaceuticals, Inc. (AMEX:ARMP) closed at $11.61 USD, losing -$0.45 (-3.73%) from the previous close of $12.06. The stock is currently mid-range between its 52-week high and low $1.17 and $16.34. With a market capitalization of about $425.31 million, Armata Pharmaceuticals, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 44.32 thousand shares, volume is running light vs its 52-week average. Headquartered in Marina del Rey, CA, Armata Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Deborah L. Birx, the company employs approximately 60 people and listed since May 20, 1994. Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Armata Pharmaceuticals, Inc. (AMEX:ARMP) shares are flat -5.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Armata Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.67, suggesting -32.69% downside. Our AI forecast model points to short-term weakness (-1.24% over two weeks), a medium-term rise (130.43% over three months), and a longer-term gain (135.95% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Armata Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.24%, with price expected at $12.72 by April 28, 2026, within a range of $11.12 to $14.26 3-Month Outlook: Projected rise of 130.43%, reaching $29.68 by July 13, 2026, with a range of $29.41 to $30.02. 1-Year Outlook: Projected gain of 135.95%, with price at $30.39 by April 14, 2027, within a range of $31.27 to $31.70.

Armata Pharmaceuticals, Inc. trades at a P/E ratio of -2.68, slightly below the S&P 500 average, with a price-to-sales ratio of 95.91 and a price-to-book ratio of -2.13 indicating negative book value, which may reflect financial stress. The P/FCF stands at -17.88, also below market averages.